Do you want to read an article? Please log in or register.
Clinical Management of Multidrug-resistant Tuberculosis in 16 European Countries
Related content
RECOMMENDED
Tuberculosis
Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet.
Bisson GP, Bastos M, Campbell JR, Bang D, Brust JC, Isaakadis P, Lange C, Menzies D, Migliori GB, Pape JW, Palmero D, Baghei P, Tabarsi P, Viiklepp P, Vilbrun S, Walsh J, Marks SM
doi: 10.1016/S0140-6736(20)31316-7.
Tuberculosis
Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes
Eur Respir J.
Collin SM, de Vries G, Lönnroth K, Migliori GB, Abubakar I, Anderson SR, Zenner D
doi: 10.1183/13993003.
RECOMMENDED
Tuberculosis
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
Lancet Infect Dis.
Knight GM, McQuaid CF, Dodd PJ, Houben RMGJ
doi: 10.1016/S1473-3099(19)30307-X.
RECOMMENDED
Tuberculosis
Multidrug Resistant Tuberculosis in Patients with HIV: Management Considerations within High-Resourced Settings
Ann Am Thorac Soc.
Wilson JW, Nilsen DM, Marks SM
doi: 10.1513/AnnalsATS.201902-185CME.
RECOMMENDED
Tuberculosis
Management of drug-resistant tuberculosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet.
Lange C, Dheda K, Chesov D, Mandalakas AM, Udwadia Z, Horsburgh CR Jr
doi: 10.1016/S0140-6736(19)31882-3.
RECOMMENDED
Tuberculosis
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
Lancet Respir Med.
von Groote-Bidlingmaier F, Patientia R, Sanchez E, Balanag V Jr, Ticona E, Segura P, Cadena E, Yu C, Cirule A, Lizarbe V, Davidaviciene E, Domente L, Variava E, Caoili J, Danilovits M, Bielskiene V, Staples S, Hittel N, Petersen C, Wells C, Hafkin J, Geiter LJ, Gupta R
doi: 10.1016/S2213-2600(18)30426-0.
RECOMMENDED
Tuberculosis
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM, Lancet Respiratory Medicine drug-resistant tuberculosis Commission group.
doi: 10.1016/S2213-2600(19)30263-2.
RECOMMENDED
Tuberculosis
All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Eur Respir J
Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, Atwood S, Ahmed S, Khan M, Sultana T, Manzur-Ul-Alam M, Vo LNQ, Lecca L, Yae K, Kozhabekov S, Tamirat M, Gelin A, Vilbrun SC, Kikvidze M, Faqirzai J, Kadyrov A, Skrahina A, Mesic A, Avagyan N, Bastard M, Rich ML, Khan U, Mitnick CD
doi: 10.1183/13993003.04345-2020
RECOMMENDED
Tuberculosis
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D, Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017.
doi: 10.1016/S2213-2600(20)30047-3.